Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Fresenius Kabi and Formycon Reach Global License Agreement to Commercialise Ustekinumab Biosimilar to J&J’s Stelara®

Feb 2, 2023

Fresenius Kabi and Formycon AG announced they have reached a global license agreement to commercialise FYB202, biosimilar to Johnson & Johnson’s Stelara®. Under the agreement, Fresenius will have the exclusive commercialisation rights in key global markets, whilst Formycon will be responsible for development and registration with health authorities.

On 19 September 2022, Formycon announced that it was developing a biosimilar to Merck’s Keytruda® (pembrolizumab).